Crescent
CBIO

Crescent (CBIO) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
WedbushMaintainedOutperform$27.00Aug 27, 2026
HC Wainwright & Co.DowngradedBuy → NeutralJun 1, 2026
HC Wainwright & Co.MaintainedBuy$22.00 from $25.00Mar 2, 2026
GuggenheimInitiated CoverageBuy$35.00Jan 21, 2026
HC Wainwright & Co.MaintainedBuy$25.00Aug 27, 2025
JefferiesInitiated CoverageBuy$26.00Aug 25, 2025
HC Wainwright & Co.Initiated CoverageBuy$25.00Aug 11, 2025
WedbushInitiated CoverageOutperform$27.00Jul 14, 2025
StifelInitiated CoverageBuy$28.00Jun 25, 2025
LifeSci CapitalInitiated CoverageOutperform$22.00Jun 18, 2025
Cantor FitzgeraldInitiated CoverageOverweightMar 21, 2025
TD CowenDowngradedBuy → HoldJul 26, 2024
HC Wainwright & Co.MaintainedNeutralJun 4, 2024
HC Wainwright & Co.DowngradedBuy → NeutralMay 6, 2024
HC Wainwright & Co.MaintainedBuy$8.00Mar 27, 2024
Capital OneInitiated CoverageOverweight$12.00Dec 22, 2023
HC Wainwright & Co.MaintainedBuy$8.00Aug 3, 2023
HC Wainwright & Co.MaintainedBuy$8.00Jun 15, 2023
HC Wainwright & Co.MaintainedBuy$8.00May 4, 2023
HC Wainwright & Co.MaintainedBuy$8.00Mar 30, 2023

Frequently asked questions

  • What is the latest analyst rating on CBIO?

    On Aug 27, 2026, Wedbush maintained Crescent at Outperform with a price target of $27.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.